These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35076812)

  • 1. Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.
    Franzoi MA; Lambertini M; Ceppi M; Bruzzone M; de Azambuja E
    Breast Cancer Res Treat; 2022 Apr; 192(2):457-462. PubMed ID: 35076812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR
    Hurvitz SA; Martin M; Press MF; Chan D; Fernandez-Abad M; Petru E; Rostorfer R; Guarneri V; Huang CS; Barriga S; Wijayawardana S; Brahmachary M; Ebert PJ; Hossain A; Liu J; Abel A; Aggarwal A; Jansen VM; Slamon DJ
    Clin Cancer Res; 2020 Feb; 26(3):566-580. PubMed ID: 31615937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
    Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
    Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
    Franzoi MA; Eiger D; Ameye L; Ponde N; Caparica R; De Angelis C; Brandão M; Desmedt C; Di Cosimo S; Kotecki N; Lambertini M; Awada A; Piccart M; Azambuja E
    J Natl Cancer Inst; 2021 Apr; 113(4):462-470. PubMed ID: 32750143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
    JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer.
    Hong J; Chen T; Ouyang L; Du N; Li A; Zhou Z; Zhang H; Xia Z; Meng J
    Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):559-566. PubMed ID: 38470447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
    J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
    Goetz MP; Okera M; Wildiers H; Campone M; Grischke EM; Manso L; André VAM; Chouaki N; San Antonio B; Toi M; Sledge GW
    Breast Cancer Res Treat; 2021 Apr; 186(2):417-428. PubMed ID: 33392835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.
    Fung S; Blair HA
    Target Oncol; 2023 Mar; 18(2):287-294. PubMed ID: 36826463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abemaciclib Shows Promise for Early Breast Cancer.
    Cancer Discov; 2017 Feb; 7(2):119-120. PubMed ID: 27986713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
    J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
    Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
    J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
    Wang H; Yee D; Potter D; Jewett P; Yau C; Beckwith H; Watson A; O'Grady N; Wilson A; Brain S; Pohlmann P; ; Blaes A
    Breast Cancer Res Treat; 2024 Apr; 204(3):589-597. PubMed ID: 38216819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
    Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
    Tolaney SM; Guarneri V; Seo JH; Cruz J; Abreu MH; Takahashi M; Barrios C; McIntyre K; Wei R; Munoz M; Antonio BS; Liepa AM; Martin M; Johnston SRD; Kellokumpu-Lehtinen PL; Harbeck N
    Eur J Cancer; 2024 Mar; 199():113555. PubMed ID: 38244363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
    Hong K; Yao L; Sheng X; Ye D; Guo Y
    Oncol Res Treat; 2021; 44(10):557-567. PubMed ID: 34515204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
    Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
    Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.